

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy [ID6470]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| <p>The committee considered the following potential equalities issues:</p> <ul style="list-style-type: none">• Transthyretin-related amyloidosis with cardiomyopathy (ATTR-CM) primarily affects older people, and,• hereditary ATTR-CM disproportionately affects people with certain genetic variants (such as Val122Ile), which are more prevalent in African, Caribbean and Hispanic populations. <p>Age and race are protected characteristics under the Equality Act 2010. But because its recommendation does not restrict access to treatment for some people over others, the committee agreed these were not equalities issues that could be addressed by this evaluation.</p> |
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| None identified |

3.	Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
None identified	

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No adverse impacts identified	

6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
None	

7.	Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Yes: section 3.16	

Approved by Associate Director: Lorna Dunning

Date: 14th November 2025